Consequently, researchers developed the homeostasis model assessment of insulin resistance (HOMA-IR) for clinical studies; however, this model is susceptible to exogenous insulin therapy and is not suitable for patients with β-cell incompetence [11, 12]. The gene discussed is INS; the disease is Insulin resistance.